Volume 11, Number 8—August 2005
Dispatch
Cost-Benefit of Stockpiling Drugs for Influenza Pandemic
Ran D. Balicer*†
, Michael Huerta*, Nadav Davidovitch*†, and Itamar Grotto*†
, Michael Huerta*, Nadav Davidovitch*†, and Itamar Grotto*†
Table 2
Cost-benefit ratios of antiviral utilization strategies*
| Strategy | Cost-benefit ratio, relative to nonintervention |
||
|---|---|---|---|
| All costs to economy | Direct healthcare costs | ||
| NI | No intervention (base case) | Ref. | Ref. |
| 1a | Therapeutic use (all patients) | 2.44 | 0.30 |
| 1b | Therapeutic use (limited to patients at high risk) | 3.68 | 1.51 |
| 2a | Preexposure long-term prophylaxis of entire population | 0.38 | 0.04 |
| 2b | Preexposure long-term prophylaxis, limited to high-risk population | 0.37 | 0.10 |
| 3a | Postexposure short-term prophylaxis for all close contacts ("ring prophylaxis"), including treatment of index patients | 2.49 | 0.27 |
*Ref., reference value of zero divided by zero.
Page created: April 23, 2012
Page updated: April 23, 2012
Page reviewed: April 23, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.